Compare COLL & IQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COLL | IQ |
|---|---|---|
| Founded | 2002 | 2009 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Consumer Electronics/Video Chains |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 984.3M |
| IPO Year | 2015 | 2017 |
| Metric | COLL | IQ |
|---|---|---|
| Price | $21.84 | $0.98 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 20 |
| Target Price | ★ $49.00 | $1.40 |
| AVG Volume (30 Days) | 751.9K | ★ 7.0M |
| Earning Date | 11-05-2026 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $780,567,000.00 | N/A |
| Revenue This Year | $7.25 | N/A |
| Revenue Next Year | $1.55 | $2.58 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 23.62 | N/A |
| 52 Week Low | $21.62 | $0.86 |
| 52 Week High | $50.79 | $2.51 |
| Indicator | COLL | IQ |
|---|---|---|
| Relative Strength Index (RSI) | 30.33 | 46.31 |
| Support Level | $21.65 | $0.97 |
| Resistance Level | $23.69 | $1.18 |
| Average True Range (ATR) | 0.87 | 0.05 |
| MACD | 0.24 | 0.01 |
| Stochastic Oscillator | 17.87 | 22.14 |
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.
Iqiyi is a leading streaming video-on-demand company in China that generates revenue mostly through a subscription basis. The platform also provides user-generated content to nonpaying users, monetized through ads. The company self-produces much of the subscription content and also generates revenue through content distribution, gaming, and IP licensing. Iqiyi competes directly with Tencent Video, Alibaba's Youku, ByteDance's MangoTV, and Bilibili. The company is 45% and 5% owned by Baidu and Xiaomi, respectively.